MiPBF

MiPBF
Clinical data
Other namesMethylisopropylbenzofuran; MIPBF; N-Methyl-N-isopropyl-3-(2-aminoethyl)benzofuran; 1-Oxa-N-methyl-N-isopropyltryptamine; 1-Oxa-MiPT
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • N-[2-(1-benzofuran-3-yl)ethyl]-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC14H19NO
Molar mass217.312 g·mol−1
3D model (JSmol)
  • CC(C)N(C)CCC1=COC2=CC=CC=C21
  • InChI=1S/C14H19NO/c1-11(2)15(3)9-8-12-10-16-14-7-5-4-6-13(12)14/h4-7,10-11H,8-9H2,1-3H3
  • Key:HNYJKEQVSSYBRE-UHFFFAOYSA-N

MiPBF, also known as N-methyl-N-isopropyl-3-(2-aminoethyl)benzofuran or as 1-oxa-N-methyl-N-isopropyltryptamine (1-oxa-MiPT), is a serotonin receptor modulator of the benzofuran family related to the psychedelic tryptamine methylisopropyltryptamine (MiPT). It is the analogue and bioisostere of MiPT in which the indole nitrogen has been replaced with an oxygen atom, making it a benzofuran rather than tryptamine derivative. The drug shows affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, and 5-HT2B receptors (IC50Tooltip half-maximal inhibitory concentration = 5,000 nM, 500 nM, and 800 nM, respectively). Its affinities for these receptors were 7-fold, 13-fold, and 1.5-fold lower than those of MiPT, respectively. MiPBF was first described in the scientific literature by Dennis McKenna and David Repke and colleagues in 1990.

See also